4.2 Article

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Alzheimer's disease and other dementias

Journal

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
Volume 12, Issue 1, Pages 2-32

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.3109/15622975.2010.538083

Keywords

Dementia; guidelines; Alzheimer; vascular dementia; Lewy body disease; fronto-temporal dementia; anti-dementia pharmaceuticals; neuropsychiatric symptoms; NPS; biological; treatment

Categories

Funding

  1. APK
  2. Austroplant
  3. BDI
  4. Beltz Test
  5. BOD
  6. Caritas Siegen
  7. Double Helix Development
  8. Eisai
  9. Friedrichverlag
  10. GE Healthcare
  11. Hogrefe
  12. IFE
  13. Janssen
  14. KDA
  15. Landesinitiative Demenz Service NRW
  16. LVR Duren
  17. Lundbeck
  18. Medical Tribune
  19. Med. Komm.
  20. Novartis
  21. Pfizer
  22. Pfrimmer Nutritia
  23. Pierrel
  24. Schwabe
  25. Thieme
  26. Urban Vogel
  27. Westermayer

Ask authors/readers for more resources

Objectives. To define a practice guideline for biological treatment of dementia and to make transparent the development of the guideline connecting the original data with the resulting recommendations. Methods. This guideline includes pharmacologic treatment considerations for patients with Alzheimer's disease, vascular dementia, DLB, and fronto-temporal dementia. Studies were selected that represent double-blind placebo-controlled trials of at least 3 months duration in patients with a diagnosis of dementia according to accepted international diagnostic criteria (for example the NINCDS/ADRDA or NINDS/AIREN criteria). Moreover, to be included studies had to fulfill a restrictive set of methodological criteria. Original studies and not meta-analyses determined the evaluation and the development of recommendations. Results. Antidementia pharmaceuticals neither cure nor arrest the disease. A modest effect of improvement of symptoms compared with placebo can be observed. Antidementia pharmaceuticals show different efficacy and side effect profiles. The type of dementia, the individual symptom constellation and the tolerability should determine what medication should be used. There are hints that combination therapy of drugs with different therapeutic mechanisms might improve the efficacy. In treating neuropsychiatric symptoms (NPS), psychosocial intervention should be the treatment of first choice. Pharmaceuticals can only be recommended when psychosocial interventions is not adequate. However, even then the side effects of pharmaceuticals limit their use. Conclusions. Depending on the diagnostic entity and the pathology treated different anti-dementia drugs can be recommended to improve symptoms. In the management of NPS, side effects limit the use of medications even when psychosocial interventions have failed. Thus, there is an urgent need to develop more efficacious medications for the treatment of dementia.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available